

July 15, 2025

To,
Listing/Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

To,
Listing/Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G-Block, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051

BSE CODE – 543998

NSE Symbol: VALIANTLAB

Dear Sir/Madam,

Subject: Outcome of the Rights Issue Committee Meeting of Valiant Laboratories Limited (the “Company”) held on July 15, 2025.

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

Further to the in-principle approval received from National Stock Exchange of India Limited vide its letter dated July 11, 2025, and BSE limited vide its letter dated July 14, 2025, we wish to inform you that the Rights Issue Committee of the Company (“the Committee”) at its meeting held today i.e. on July 15, 2025, has, *inter alia*, considered and approved the following terms of the Rights Issue:

Sr No	Particulars	Details
1	Type of securities proposed to be issued	Fully paid-up Equity Shares of face value of ₹10/- each (“Rights Equity Shares”)
2	Type of issuance	Rights Issue of fully paid-up Equity Shares
3	Total number of securities proposed to be issued	Up to 1,08,62,500 fully paid-up Equity Shares of face value of ₹ 10/- each
4	Issue Price	₹75/- per Rights Equity Share (including premium of ₹65/- per Rights Equity Share and Face Value of ₹10/- each).
5	Issue Size	₹8146.88 lakhs
6	Terms of Payment	The full amount of the Issue Price being ₹75/- will be payable on application.
7	Record Date	July 19, 2025, for the purpose of determining the equity shareholders entitled to receive the rights entitlement in the Rights Issue (“Eligible Equity Shareholders”)
8	Rights Issue Period	<p>Rights Issue Opening Date: Monday, July 28, 2025.</p> <p>*Last Date of Market Renunciations: Tuesday, August 05, 2025.</p> <p>**Rights Issue Closing Date: Friday, August 08, 2025.</p> <p><i>*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in</i></p>

www.valiantlabs.in | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.

T: 022-49712001 / 49717220 / 49717221 | **E:** investor@valiantlabs.in

		<p><i>such a manner that the Rights Entitlements are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.</i></p> <p><i>**Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.</i></p>
9	Rights Entitlement ISIN	Will be announced separately
10	Rights Entitlement Ratio	1 (One) Rights Equity Shares of ₹10/- each for every 4(Four) Equity Shares of ₹10/- each held by the Eligible Equity Shareholders in the Company as on the record date, with the right to renounce
11	Outstanding Equity Shares prior to the Rights Issue	4,34,50,000 Equity Shares of ₹10/- each
12	Outstanding Equity Shares post Rights Issue (assuming full subscription)	5,43,12,500 Equity Shares of ₹10/- each (assuming full subscription)

Further the Committee adopted the Letter of Offer to be filed with BSE Limited, National Stock Exchange of India Limited and the same shall be dispatched to the Eligible Equity Shareholders of the Company as on the Record Date in due course.

The Committee Meeting held today concluded at 4:15 P.M.

This intimation is also being uploaded on the Company's website at www.valiantlabs.in

We request you to take the same on record.

Thanking you,

Yours Faithfully,

For **Valiant Laboratories Limited**

Akshay Gangurde

Company Secretary & Compliance Officer

M. No.: A70561